Interferon Alpha Therapy for Cervical CINI and HPV Infection

The purpose of the study is to evaluate the efficacy of interferon treatment for HPV infection shedding and early CIN change. Women aging from 20-40 years will be enrolled in the study. The treatment will be held in two arms. One arm will be administered only vaginal gel interferon treatment. The other arm will receive both vaginal gel interferon and rectal suppositories with interferon dosing 3,000,000 IU. In the beginning of the study all patient will have cervical pap smear and HPV typing. HPV testing will be done using real time PCR method to determine the subtype of HPV (16,18,31,33,35,39,45,51,52,56,59,68). At the beginning and at the end of the study all patient will have histology test. Histology test will be done Giemsa staining and evaluated by WHO 2014 classification of cervical histology including CINI, CINII, CINIII, cervical cancer in situ and further. Pap smear will be evaluated by Bethesda classification. Immunohistology staining will be done on the cervical tissue using anti-CD3 and anti-CD19 to evaluate the B cell invasion into the cervix.